RAFAEL HOLDINGS, INC. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
RAFAEL HOLDINGS, INC. (RFL) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $1.77 million for the 12-month period ending 2024-07-31, per its 10-K/A filed 2024-12-20.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2024-12-20
- RAFAEL HOLDINGS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-07-31 was $251.00K.
- RAFAEL HOLDINGS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-04-30 was $945.00K.
- RAFAEL HOLDINGS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-01-31 was $399.00K, a 187.05% increase year-over-year.
- RAFAEL HOLDINGS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-10-31 was $177.00K, a 1080.00% increase year-over-year.
- RAFAEL HOLDINGS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was $1.77M, a 1050.65% increase from fiscal 2023.
- RAFAEL HOLDINGS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was $154.00K.
- RAFAEL HOLDINGS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was -$45.00K.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2024-07-31 | $251.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $1.20M derived: sum of 2 quarters · filed 2024-12-20 | $1.59M derived: sum of 3 quarters · filed 2024-12-20 | $1.77M 10-K/A · filed 2024-12-20 |
| 2024-04-30 | $945.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | $1.34M derived: sum of 2 quarters · filed 2024-06-14 | $1.52M 10-Q · filed 2024-06-14 | $1.52M derived: sum of 4 quarters · filed 2024-12-20 |
| 2024-01-31 | $399.00K 10-Q · filed 2024-03-14 | $576.00K 10-Q · filed 2024-03-14 | $576.00K derived: sum of 3 quarters · filed 2024-12-20 | $576.00K derived: sum of 4 quarters · filed 2024-12-20 |
| 2023-10-31 | $177.00K 10-Q · filed 2023-12-14 | $177.00K derived: sum of 2 quarters · filed 2024-12-20 | $177.00K derived: sum of 3 quarters · filed 2024-12-20 | $316.00K derived: sum of 4 quarters · filed 2024-12-20 |
| 2023-07-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $0.00 derived: sum of 2 quarters · filed 2024-12-20 | $139.00K derived: sum of 3 quarters · filed 2024-12-20 | $154.00K 10-K/A · filed 2024-12-20 |
| 2023-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | $139.00K derived: sum of 2 quarters · filed 2024-06-14 | $154.00K 10-Q · filed 2024-06-14 | |
| 2023-01-31 | $139.00K 10-Q · filed 2024-03-14 | $154.00K 10-Q · filed 2024-03-14 | ||
| 2022-10-31 | $15.00K 10-Q · filed 2023-12-14 | |||
| 2022-07-31 | -$45.00K 10-K · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |